Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, ...

The new suite of capabilities will accelerate development timelines by enabling both monoclonal antibody (mAb) production and ...

"ESMO 2025: MSD’s ADC leapfrogs to Phase III in colorectal cancer " was originally created and published by Clinical Trials ...

Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of ...

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by ...

In this episode, Ollie challenges himself with complex Korean verb forms and learns how to express seeing an imaginary dog ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

As of 2023, the ABC data indicated that in older adults (=65 years), the prevalence of invasive PD attributed to Capvaxive-unique serotypes was more than triple (34.8%) that of PCV20-unique serotypes ...

“Salarius is now fully compliant with all Nasdaq listing requirements, marking another critical step in our planned merger with Decoy Therapeutics,” said Mark J. Rosenblum, acting CEO and CFO of ...

OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug ...

Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage ...